Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:22:1-10.
doi: 10.1007/8904_2014_371. Epub 2015 Feb 18.

Innate and Adaptive Immune Response in Fabry Disease

Wladimir Mauhin  1 , Olivier Lidove, Elisa Masat, Federico Mingozzi, Kuberaka Mariampillai, Jean-Marc Ziza, Olivier Benveniste
Affiliations

Innate and Adaptive Immune Response in Fabry Disease

Wladimir Mauhin et al. JIMD Rep. 2015.

Abstract

Fabry disease is an X-linked lysosomal storage disease in which mutations of the gene (GLA) cause a deficiency of the lysosomal hydrolase α-galactosidase A (α-Gal). This defect results in an accumulation of glycosphingolipids, primarily globotriaosylceramide (Gb3) which causes a multisystemic vasculopathy. Available since 2001 in Europe, enzyme replacement therapy consists in the administration of agalsidase, a recombinant form of α-galactosidase A. Enzyme replacement therapy was shown to improve the global prognosis but allowed partial success in preventing critical events such as strokes and cardiac arrests. As in most lysosomal storage diseases, frequent immune reactions have been described in naive Fabry disease patients. Humoral immune responses following enzyme replacement therapy have also been described, with unclear consequences on the progression of the disease. While cost-effectiveness of enzyme replacement therapy in Fabry disease begins to be questioned and new therapeutic strategies arise such as chaperone or gene therapy, it appears necessary to better understand the immune responses observed in the treatment of naive patients and during enzyme replacement therapy with agalsidase. We propose a comprehensive review of the available literature concerning both innate and adaptive responses observed in Fabry disease. We particularly highlight the probable role of the toll-like receptor 4 (TLR4) and CD1d pathways triggered by Gb3 accumulation in the development of local and systemic inflammation that could lead to irreversible organ damages. We propose an immunological point of view of Fabry disease pathogenesis involving immune cells notably the invariant natural killer T cells. We finally review anti-agalsidase antibodies, their development and impact on outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Innate response observed in Fabry disease. APCs antigen-presenting cells, Gb3 globotriaosylceramide, iNKTs invariant natural killer T cells (CD4+ or DN, double negative subsets), PBMCs peripheral blood mononuclear cells, TCR T-cell receptor, TLR4 toll-like receptor 4
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812–2817. doi: 10.1073/pnas.0712309105. - DOI - PMC - PubMed
    1. Anders H-J, Banas B, Schlöndorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol. 2004;15:854–867. doi: 10.1097/01.ASN.0000121781.89599.16. - DOI - PubMed
    1. Balreira A, Macedo MF, Girão C, et al. Anomalies in conventional T and invariant natural killer T-cell populations in Fabry mice but not in Fabry patients. Br J Haematol. 2008;143:601–604. - PubMed
    1. Banas MC, Banas B, Hudkins KL, et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol. 2008;19:704–713. doi: 10.1681/ASN.2007040395. - DOI - PMC - PubMed
    1. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77–86. doi: 10.7326/0003-4819-146-2-200701160-00148. - DOI - PubMed

LinkOut - more resources

  NODES
admin 1
INTERN 3
twitter 2